Very-Low-Dose Oral Minoxidil in Male Androgenetic Alopecia: A Study with Quantitative Trichoscopic Documentation

September 2019 in “ Journal of The American Academy of Dermatology ”

Rodrigo Pirmez, Corina Isabel Salas-Callo

oral minoxidil androgenetic alopecia pedal edema hair shedding body hypertrichosis OM AGA

Studysummary This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study investigated the use of very low dose oral minoxidil (OM) as a monotherapy in the treatment of male androgenetic alopecia (AGA). The results showed improvement or stabilization in a percentage of individual patients for all parameters analyzed, but statistical analysis did not show a significant variation in the group as a whole. Adverse effects reported were pedal edema, hair shedding, and body hypertrichosis. The study suggests that higher doses of OM might be necessary to produce significant effects in men.

View this study on jaad.org →

Discuss this study in the Community →

Research cited in this study

5 / 5 results

research Effectiveness and Safety of Low-Dose Oral Minoxidil in Male Androgenetic Alopecia

52 citations , May 2019 in “Journal of The American Academy of Dermatology”

This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with male androgenetic alopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.

research Female Pattern Hair Loss: A Pilot Study Investigating Combination Therapy with Low-Dose Oral Minoxidil and Spironolactone

80 citations , December 2017 in “International Journal of Dermatology”

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

research Androgenetic Alopecia: An Update Of Treatment Options

110 citations , August 2016 in “Drugs”

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

research Quality of Life Assessment in Male Patients with Androgenetic Alopecia: Results of a Prospective, Multicenter Study

101 citations , January 2012 in “Annals of Dermatology”

In this study, researchers found that androgenetic alopecia significantly harms quality of life, particularly in younger patients, those with more severe or long-term alopecia, and those who have sought non-medical hair care.

research Topical Minoxidil Therapy in Hereditary Androgenetic Alopecia

55 citations , February 1985 in “Archives of Dermatology”

This study found that 32% of patients with hereditary male pattern baldness experienced cosmetically acceptable hair growth after applying topical minoxidil twice daily, with no serious side effects reported.